Cefepime vs carbapenems for treating third-generation cephalosporin-resistant AmpC β-lactamase-hyperproducing Enterobacterales bloodstream infections: a multicenter retrospective study

作者
Baptiste Hoellinger,Charlotte Kaeuffer,Pierre Boyer,Nicolas Lefèbvre,Yves Hansmann,Amandine Robert,François Séverac,Alain Gravet,François Danion,Yvon Ruch,Axel Ursenbach
出处
期刊:International Journal of Infectious Diseases [Elsevier BV]
卷期号:134: 273-279 被引量:19
标识
DOI:10.1016/j.ijid.2023.07.004
摘要

OBJECTIVES: AmpC β-lactamase-hyperproducing Enterobacterales (ABLHE) bloodstream infections (BSI) are emerging and leading to therapeutic challenges worldwide. Prescriptions of carbapenems may lead to the emergence of resistance. This study aimed to compare cefepime with carbapenems for the treatment of third-generation cephalosporin-resistant ABLHE BSI. METHODS: This retrospective multicenter study included patients with ABLHE BSI from two tertiary hospitals in France, between July 2017 and July 2022. Non-AmpC-producing Enterobacterales, extended-spectrum β-lactamase, and carbapenemase-producing Enterobacterales were excluded. Cefepime was prescribed only in case of minimal inhibitory concentration ≤1 mg/l. The primary outcome was 30-day in-hospital mortality from the date of index blood culture. Secondary outcomes were infection recurrence and treatment toxicity. An inverse probability of treatment weighting approach was used to balance the baseline characteristics between the two groups. RESULTS: We analyzed 164 BSI, which included 77 in the cefepime group and 87 in the carbapenem group. In the weighted cohort, the 30-day mortality rates were similar between the cefepime group (23.3%) and the carbapenem group (19.6%) with a relative risk of 1.19 (95% confidence interval, 0.61-2.33 P = 0.614). No significant difference in recurrence or toxicity was found between the two groups. CONCLUSION: This study adds evidence in favor of the use of cefepime for treating third-generation cephalosporin-resistant ABLHE BSI in case of minimal inhibitory concentration ≤ 1 mg/l, which could spare carbapenems.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
ASBL完成签到,获得积分10
1秒前
迷你的灵阳完成签到,获得积分10
1秒前
Starshine完成签到,获得积分10
2秒前
Dominos完成签到,获得积分10
2秒前
天天向上的应助被hgf采纳,获得10
2秒前
Agnes发布了新的文献求助10
2秒前
徐宇鹏完成签到 ,获得积分10
2秒前
缓慢的冬云完成签到,获得积分0
3秒前
早起完成签到,获得积分10
3秒前
网民完成签到,获得积分10
4秒前
追梦完成签到,获得积分10
4秒前
北柒陌人完成签到,获得积分10
5秒前
孤独芷烟完成签到,获得积分10
5秒前
1459完成签到,获得积分10
5秒前
懵懂的小白菜完成签到,获得积分10
5秒前
Wesley完成签到,获得积分10
5秒前
大王的大王完成签到,获得积分10
6秒前
老迟到的涫完成签到,获得积分10
6秒前
陈明娃完成签到,获得积分10
7秒前
大头儿子完成签到 ,获得积分10
8秒前
8秒前
melosy完成签到,获得积分10
8秒前
桐桐的应助被积极的乐瑶采纳,获得10
9秒前
贝北呗完成签到,获得积分10
9秒前
9秒前
feiyang完成签到,获得积分10
9秒前
ty6789完成签到 ,获得积分10
11秒前
寒冷采梦完成签到,获得积分10
11秒前
dy完成签到,获得积分10
11秒前
11秒前
saa完成签到,获得积分10
11秒前
脑袋瓜子完成签到,获得积分10
12秒前
杨老师完成签到 ,获得积分10
13秒前
小乐完成签到,获得积分10
13秒前
王亮发布了新的文献求助10
13秒前
Victoria完成签到,获得积分10
13秒前
无情的聋五完成签到 ,获得积分10
13秒前
feibai完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039